Reflux Pharmaceuticals

Navi Mumbai, India Founded: 2020 • Age: 6 yrs
Active pharmaceutical ingredients and intermediates are manufactured by Reflux Pharmaceuticals.
Annual revenue $2.1M Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Reflux Pharmaceuticals

Reflux Pharmaceuticals is a company based in Navi Mumbai (India) founded in 2020. Reflux Pharmaceuticals offers products and services including Tolfenamic Acid and Flavoxate HCl.

  • Headquarter Navi Mumbai, India
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Reflux Pharmaceuticals Private Limited
  • Date of Incorporation 03 Feb, 2020
  • Jurisdiction Thane, Maharashtra, India
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $2.14 M (USD)
    386.06
    as on Mar 31, 2022
  • Net Profit
    $31.63 K (USD)
    -5.71
    as on Mar 31, 2022
  • EBITDA
    $58.71 K (USD)
    16.11
    as on Mar 31, 2022
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Reflux Pharmaceuticals

Reflux Pharmaceuticals offers a comprehensive portfolio of products and services, including Tolfenamic Acid and Flavoxate HCl.

Product name locked
Category locked
Primary

Tolfenamic Acid is produced as a non-steroidal anti-inflammatory drug for pharmaceutical applications.

Product name locked
Category locked
Locked

Flavoxate HCl is manufactured for anti-spasmodic uses and treatment of urinary incontinence.

Funding Insights of Reflux Pharmaceuticals

Investors in Reflux Pharmaceuticals

Reflux Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Eiko LifeSciences Limited.

All
Institutional
Investor Description Founded Year Domain Location
Manufacturing and exporting of speciality chemicals and pharma intermediates in India.
Locked Locked Locked
Premium access

Investor details for Reflux Pharmaceuticals

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Reflux Pharmaceuticals

Investments
Premium access

Investment portfolio details for Reflux Pharmaceuticals

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Reflux Pharmaceuticals

Premium access

Detailed financials for Reflux Pharmaceuticals

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Reflux Pharmaceuticals Comparisons

Reflux Pharmaceuticals Primary company
Description
Active pharmaceutical ingredients and intermediates are manu...
Location
Navi Mumbai, India
Founded Year
2020
Annual Revenue
$2.14 M (USD)
Net Profit
$31.63 K (USD)
EBITDA
$58.71 K (USD)
Employees
Not available
Premium access

Peer comparison for Reflux Pharmaceuticals

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Reflux Pharmaceuticals

Premium access

Detailed competitors of Reflux Pharmaceuticals

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Reflux Pharmaceuticals

Premium access

Complete news archive for Reflux Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Reflux Pharmaceuticals

Reflux Pharmaceuticals was founded in 2020 and raised its 1st funding round 3 years after it was founded.

Reflux Pharmaceuticals is headquartered in Navi Mumbai, India. It is registered at Navi Mumbai, Maharashtra, India.

Annual revenue of Reflux Pharmaceuticals is $2.14M as on Mar 31, 2022.

Reflux Pharmaceuticals was established in 2020 and is based in Navi Mumbai, India. The company operates within the pharmaceutical sector, focusing on the production of active pharmaceutical ingredients (APIs) and chemical intermediates. These materials are supplied to support drug manufacturing processes. Operations emphasize quality-controlled synthesis and formulation, serving clients in the global healthcare industry. The firms activities align with regulatory standards for pharmaceutical components.

Reflux Pharmaceuticals offers Tolfenamic Acid and Flavoxate HCl.

Reflux Pharmaceuticals has 1 investor. Key investors include Eiko LifeSciences Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available